Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hee-Young | - |
dc.contributor.author | Kim, Sun-Young | - |
dc.contributor.author | Kim, Ok-Jin | - |
dc.contributor.author | Song, Jin Woo | - |
dc.date.accessioned | 2024-08-14T05:02:01Z | - |
dc.date.available | 2024-08-14T05:02:01Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 1323-7799 | - |
dc.identifier.issn | 1440-1843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26548 | - |
dc.description.abstract | Background and Objective Air pollution affects clinical course and prognosis of idiopathic pulmonary fibrosis (IPF). However, the effect of individual exposure to air pollutants on disease progression is unclear. We aimed to identify the effect of individual exposure to nitrogen dioxide (NO2) and particulate matter (aerodynamic diameter <= 10 mu m [PM10]) on disease progression in patients with IPF. Methods The serial lung function data of 946 IPF patients (mean age: 65.4 years, male: 80.9%) were analysed. Individual-level long-term exposures to NO2 and PM10 at the residential addresses of patients were estimated using a national-scale exposure prediction model, constructed based on air quality regulatory monitoring data. Progression was defined as a relative decline (>= 10%) in forced vital capacity. Individual- and area-level covariates were adjusted in the primary analysis model. Results Overall, 547 patients (57.8%) experienced progression during a median follow-up of 1.0 year (interquartile range: 0.4-2.6 years). In the primary model, a 10-ppb increase in NO2 concentration was associated with a 10.5% increase in the risk of progression (hazard ratio [HR] = 1.105; 95% CI = 1.000-1.219) in patients with IPF. There was also an increasing trend of progression in patients with IPF according to the second to fourth quartiles of NO2 (Q2 [HR = 1.299; 95% CI = 0.972-1.735], Q3 [1.409; 1.001-1.984], Q4 [1.598; 1.106-2.310]) compared to the first quartile. We found no association between PM10 and progression in IPF patients. Conclusion Our data suggest that increased individual exposure to NO2 can increase the risk of progression in patients with IPF. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/resp.14373 | - |
dc.identifier.scopusid | 2-s2.0-85138254030 | - |
dc.identifier.wosid | 000857879400001 | - |
dc.identifier.bibliographicCitation | RESPIROLOGY | - |
dc.citation.title | RESPIROLOGY | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | FORCED VITAL CAPACITY | - |
dc.subject.keywordPlus | AIR-POLLUTION | - |
dc.subject.keywordPlus | PARTICLES | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | STANDARDIZATION | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | INDOOR | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | NO2 | - |
dc.subject.keywordAuthor | air pollutant | - |
dc.subject.keywordAuthor | disease progression | - |
dc.subject.keywordAuthor | idiopathic pulmonary fibrosis | - |
dc.subject.keywordAuthor | lung function | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.